|
FDA Funds Comparison Study of Prograf vs. Generic Counterparts
The FDA has given $2.7 million to University of Cincinnati researchers to study whether generic versions of the transplant drug Prograf have the same efficacy as Astellas Pharma’s branded product.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives